Almirall looks to robust 2012 despite higher losses
Total turnover for the year came in at 768 million euros, down 13 per cent on 2010, with greater than 50% declines in sales for cholesterol-lowerer Prevencor (atorvastatin) licensed from Pfizer and antidepressant Esertia (escitalopram) licensed from Lundbeck.
Sales of the two drugs came in at just over 30 million euros apiece, and were both affected by Spanish healthcare reforms designed to cut the country's medicines spending. Another in-licensed product - SkyePharma's Solaraze (sodium diclofenac) for actinic keratosis - grew 7% to 27 million euros.
Meanwhile, sales of Almirall's proprietary lines held up a little better. Its top-selling antihistamine product Ebastel (ebastine) dipped slightly to 116 million euros in 2011, while migraine treatment Almogran (almotriptan) grew 3% to $50m.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze